ArticleNanoscale advances2026
Selective magnetic particle imaging of CD44 expressing cells using iron oxide nanoprobes functionalized with chemically modified hyaluronan.
Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hyaluronan (HA) is a naturally occurring biocompatible and non-immunogenic linear anionic glycosaminoglycan. In an attempt to enhance the selective binding of HA to the cluster of differentiation 44 (CD44), we recently identified a novel chemically modified HA derivative (referred to as G2HA) with improved affinity to CD44 compared to the native HA polymer. In this study, we aimed at conjugating G2HA to iron oxide nanoparticles (IONPs) and assessing the uptake of the G2HA-IONP nanocomposite by CD44 expressing cells, namely 4T1 breast cancer cells. In addition, the utility of G2HA-IONPs as efficient contrast agents for Magnetic Particle Imaging (MPI) was studied. The IONPs were synthesized by the thermal decomposition method, and G2HA was conjugated to the nanoparticles by the ligand exchange method. HA-IONPs were prepared similarly for comparison. The uptake of G2HA-IONPs by 4T1 breast cancer cells was HA-receptor dependent, and higher than that of HA-IONPs at the same iron concentration as validated in multiple assays. The cell viability assay verified that G2HA-IONPs were biocompatible at the highest tested dose. The suitability of G2HA-IONPs as MPI contrast agents was tested. MPI of cells that received the nanoparticles demonstrated that the improved uptake of G2HA-IONPs translated into more intense signals, with a 2.4-fold MPI signal enhancement compared to those from cells that received HA-IONPs. Overall, the findings of this study validated the role of the modified HA derivative (G2HA) in enhancing the uptake of iron oxide nanoparticles and asserted the potential applicability of the developed G2HA-IONPs for selective imaging of CD44-expressing cells and as a potential vehicle for drug delivery.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.